News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue



6/23/2011 9:03:13 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCBB: ARNI) announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with AvastinĀ® and will continue toward completion.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES